CyBio AG: Turnover stable. Cash flow stopped. Consistent continuation of sustainable recapitalization

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Jena, March 17th, 2009; The CyBio Group (German Stock Exchange,
General Standard, ISIN Number DE005412308) closes the year 2008 with
a turnover of 16.6 million EUR (previous year: 19.16 million EUR).
Adjusting previous year's turnover to the turnover of the CLS
Laborautomationssysteme GmbH (former accelab GmbH) and CyBio France
in the amount of 3.58 million EUR, turnovers in 2008 increase of
106.5% compared to the previous year.
The preliminary consolidated income after taxes amounts to a loss of
approximately 4.2 million EUR (previous year: -4.5 million EUR), of
which 2.1 million EUR are ascribed to special effects. The EBIT in
2008 is approximately -3.8 million EUR.
The annual result was primarily burdened with the depreciation on
assets of the CLS and losses of the legal entities "Northern Europe"
and "Japan".

The need for restructuring the subsidiaries CLS and USA was already
visible in 2007. Furthermore, in the course of 2008, it was deemed
necessary to reorganize the other shares of the Group, including
Northern Europe and Japan.
By initiating immediate action, the US subsidiary was able to
turnaround its operating loss in 2008 with a successful turnover. In
the Japanese and British subsidiaries, adjustments to the
distribution strategy were carried out, and significant increases in
sales and improvements can be expected in 2009. With an asset deal
the CLS has been positioned to pass into an orderly liquidation, thus
the threatening liquidity outflows for the CyBio Group have
successfully been stopped.

The company focuses on the consistent continuation of the
refurbishment and expects a balanced result for 2009, which will
already be visible in the first quarterly results.

Necessary steps included the realignment of the sales strategy and
the streamlining of the management.
Other measures comprised especially the targeted revision of the
product portfolio, as well as the introduction of new products, which
will make new market segments possible for the CyBio Group.
With the Analytik Jena AG's majority shareholding (51.19%) of the
CyBio AG in February 2009, sales, development and innovation skills
are combined, and new market opportunities are established for both
companies. The participation offers both concerns the possibility to
act together globally from Germany and thus use synergy effects in
the interest of their customers.

The current situation and further prospects of the company CEO Holger
Wolf comments as follows: "With the initiated renovation we made
crucial strategic steps, so that for 2009 we expect to be in the
black. Basically, CyBio has the potential but not the critical size
to make significant investments in future growth, thus the takeover
by the Analytik Group Jena is essential. Particularly in
international sales as well as in the development and the efficiency
of the production significant potential is suspected."

Contact:
CyBio AG
Goeschwitzer Str. 40
07745 Jena, Germany
Phone +49.3641.351 401
Fax +49.3641.351 409
E-mail: irpr@cybio-ag.com

--- End of Message ---

CyBio AG
Göschwitzer Straße 40 Jena Germany

WKN: 541230; ISIN:
DE0005412308; Index: CDAX;
Listed: General Standard in Frankfurter Wertpapierbörse, Freiverkehr
in Bayerische Börse München,
Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt
in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.